Drug intelligence / Profile preview

CX-052075

Development stage: Approved
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CX-052075 is a **nucleoside-modified mRNA vaccine antigen** used in Moderna's MNEXSPIKE COVID-19 vaccine. It encodes a SARS-CoV-2 Omicron LP.8.1 spike immunogen focused on the **N-terminal domain and receptor-binding domain** rather than the full-length spike, and is delivered in a lipid nanoparticle formulation for **intramuscular** administration to induce neutralizing antibody and cellular immune responses against SARS-CoV-2. The product was developed by Moderna for prevention of COVID-19 and, as the active substance in MNEXSPIKE, received U.S. approval in 2025 for active immunization in indicated higher-risk populations.

Brand names: MNEXSPIKE
Other names: covid-19 vaccine, mrna

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on CX-052075.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX-052075.

Explore the full profile